Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol

Journal of Cardiovascular Electrophysiology

Volumn 14, Issue 6, 2003, Pages 567-573

  Leite, Luiz R ^a   Fenelon, Guilherme ^b   Simoes Jr , Aloyr ^b   Silva, Georgia G ^b   Friedman, Paul A ^a   De Paola, Angelo A V ^b  

^a MAYO CLINIC   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Amiodarone; Chronic chagasic cardiomyopathy; Electrophysiologic study; Sotalol; Ventricular tachycardia

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; SOTALOL;

ADULT; ANAMNESIS; ARTICLE; CARDIOMYOPATHY; CHAGAS DISEASE; CHRONIC DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; ELECTROPHYSIOLOGY; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HEALTH STATUS; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE TACHYCARDIA; HEMODYNAMIC MONITORING; HEMODYNAMICS; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MORALITY; MORTALITY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT PLANNING;

ADULT; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; BRAZIL; CHAGAS CARDIOMYOPATHY; DEATH, SUDDEN, CARDIAC; DRUG THERAPY, COMBINATION; ELECTRIC STIMULATION THERAPY; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PATIENT DISCHARGE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; SOTALOL; STROKE VOLUME; SURVIVAL ANALYSIS; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0038820106     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1540-8167.2003.02278.x     Document Type: Article

References (24)

1. WHO Expert Committee on the Control of Chagas Disease: Control of Chagas disease. World Health Organ Tech Rep Ser 1991;811:1-95.
2. Giniger AG, Retyk EO, Laino RA, Sananes EG, Lapuente AR: Ventricular tachycardia in Chagas' disease. Am J Cardiol 1992;70:459-462.
3. Pan American Organization: Health Conditions in the Americas. Scientific Publication 524. Volume 1. Washington, DC: Pan American Health Organization, 1990, p. 160.
4. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators: A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-1583.
5. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, Greene HL, Boczor S, Domanski M, Follmann D, Gent M, Roberts RS: Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000;21:2071-2078.
6. Sheldon R, Connolly S, Krahn A, Roberts R, Gent M, Gardner M: Identification of patients most likely to benefit from implantable cardioverterdefibrillator therapy: The Canadian Implantable Defibrillator Study. Circulation 2000;101:1660-1664.
7. de Paola AA, Horowitz LN, Miyamoto MH, Pinheiro R, Ferreira DF, Terzian AB, Cirenza C, Guiguer N Jr, Portugal OP: Angiographic and electrophysiologic substrates of ventricular tachycardia in chronic chagasic myocarditis. Am J Cardiol 1990;65:360-363.
8. Sosa E, Scanavacca M, D'Avila A, Piccioni J, Sanchez O, Verlarde JL, Silva M, Reolao B: Endocardial and epicardial ablation guided by non-surgical transthoracic epicardial mapping to treat recurrent ventricular tachycardia. J Cardiovasc Electrophysiol 1998;9:229-239.
9. Mendoza I, Camardo J, Moleiro F, Castellanos A, Medina V, Gomez J, Acquatella H, Casal H, Tortoledo F, Puigbo J: Sustained ventricular tachycardia in chronic chagasic myocarditis: Electrophysiologic and pharmacologic characteristics. Am J Cardiol 1986;57:423-427.
10. Leite LR, Fenelon G, Paes AT, de Paola AA: The impact of syncope during clinical presentation of sustained ventricular tachycardia on total and cardiac mortality in patients with chronic chagasic heart disease. Arq Bras Cardiol 2001;77:446-452.
11. Mason JW: Mindfully mining MUSTT. Multicenter Unsustained Tachycardia Trial. J Am Coll Cardiol 2001;38:352-354.
12. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G: A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341:1882-1890.
13. Mason JW: A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med 1993;329:445-451.
14. Horowitz LN, Greenspan AM, Spielman SR, Webb CR, Morganroth J, Rotmensch H, Sokoloff NM, Rae AP, Segal BL, Kay HR: Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease. Am J Cardiol 1985;55:367-371.
15. Waller TJ, Kay HR, Spielman SR, Kutalek SP, Greenspan AM, Horowitz LN: Reduction in sudden death and total mortality by antiarrhythmic therapy evaluated by electrophysiologic drug testing: Criteria of efficacy in patients with sustained ventricular tachyarrhythmia. J Am Coll Cardiol 1987;10:83-89.
16. Naccarelli GV, Prystowsky EN, Jackman WM, Heger JJ, Rahilly GT, Zipes DP: Role of electrophysiologic testing in managing patients who have ventricular tachycardia unrelated to coronary artery disease. Am J Cardiol 1982;50:165-171.
17. Wellens HJ, Brugada P, Stevenson WG: Programmed electrical stimulation of the heart in patients with life-threatening ventricular arrhythmias: What is the significance of induced arrhythmias and what is the correct stimulation protocol? Circulation 1985;72:1-7.
18. Kuhlkamp V, Mewis C, Mermi J, Bosch RF, Seipel L: Suppression of sustained ventricular tachyarrhythmias: A comparison of d,l-sotalol with no antiarrhythmic drug treatment. J Am Coll Cardiol 1999;33:46-52.
19. Nademanee K, Hendrickson J, Kannan R, Singh BN: Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: Potent suppression of spontaneously occurring tachyarrhythmias versus inconsistent abolition of induced ventricular tachycardia. Am Heart J 1982;103:950-959.
20. Maury P, Zimmermann M, Metzger J, Reynard C, Dorsaz P, Adamec R: Amiodarone therapy for sustained ventricular tachycardia after myocardial infarction: Long-term follow-up, risk assessment and predictive value of programmed ventricular stimulation. Int J Cardiol 2000;76:199-210.
21. Wyse DG, Talajic M, Hafley GE, Buxton AE, Mitchell LB, Kus TK, Packer DL, Kou WH, Lemery R, Santucci P, Grimes D, Hickey K, Stevens C, Singh SN: Antiarrhythmic drug therapy in the Multicenter UnSustained Tachycardia Trial (MUSTT): Drug testing and as-treated analysis. J Am Coll Cardiol 2001;38:344-351.
22. Hamer AW, Rubin SA, Peter T, Mandel WJ: Factors that predict syncope during ventricular tachycardia in patients. Am Heart J 1984;107:997-1005.
23. Landolina M, Mantica M, Pessano P, Manfredini R, Foresti A, Schwartz PJ, De Ferrari GM: Impaired baroreflex sensitivity is correlated with hemodynamic deterioration of sustained ventricular tachycardia. J Am Coll Cardiol 1997;29:568-575.
24. Silva RM, Tavora MZ, Gondim FA, Metha N, Hara VM, Paola AA: Predictive value of clinical and electrophysiological variables in patients with chronic chagasic cardiomyopathy and nonsustained ventricular tachycardia [Portuguese]. Arq Bras Cardiol 2000;75:33-47.